| Patient | Billie Holiday |
|---|---|
| Date of birth | 1993-04-07 |
| Identifiers | MRN HR-ML010-SYN; SSN (made up) 000-10-4472 |
| Document date | 2026-10-19 |
| Author | Constance Mayfield, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-month recovery, alcohol, liver, and mood review. [S]
Ms. Holiday returns six months after starting buprenorphine. She has taken 16 mg every day since the return to use before the three-month visit and has used no heroin or other opioids for three months. The early refill and travel letter worked on her last tour. She drinks one drink on some performance nights and none otherwise. Her dental abscess was drained by the dentist the week of her sick visit, and the tooth has since had root canal treatment; she finished the amoxicillin and needed the pain tablets for only three days. She sleeps better and enjoys singing again. She sees her counselor weekly and her peer recovery coach every two weeks. [S]
| Element | Detail |
|---|---|
| Opioid use | None for three months |
| Buprenorphine | 16 mg daily, no gaps |
| Alcohol | One drink on some performance nights |
| Tooth | Abscess drained; root canal completed; no pain |
| Mood | PHQ-9 4 |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy better; weight up 1.6 kg |
| Ears, nose, mouth, and throat | Negative | No tooth pain or swelling |
| Psychiatric | Negative | Mood good; PHQ-9 score 4; no thoughts of suicide or self-harm |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Buprenorphine 8 mg and naloxone 2 mg sublingual film: half a film (4 mg) on day 1, then one film (8 mg) under the tongue daily | One film under the tongue daily after a 4 mg first dose | Sublingual route | 2026-04-20 to 2026-04-27 | completed | S |
| Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily | Two films under the tongue once daily | Sublingual route | 2026-04-27 | active | S |
| Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils; call 911 | One spray (4 mg) in one nostril for suspected overdose; repeat every 2 to 3 minutes if there is no response | Nasal route | 2026-04-20 | active | S |
| Acamprosate 333 mg delayed-release oral tablet, two tablets (666 mg) by mouth three times daily | Two tablets by mouth three times daily | Oral route | 2026-04-27 | active | S |
| Thiamine 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-04-20 to 2026-10-19 | completed | S |
| Amoxicillin 500 mg oral capsule, one capsule by mouth three times daily for seven days | One capsule by mouth three times daily for seven days | Oral route | 2026-09-21 to 2026-09-28 | completed | S |
| Ibuprofen 400 mg oral tablet, one tablet by mouth every 6 to 8 hours with food as needed for tooth pain, for up to five days | One tablet by mouth every 6 to 8 hours with food as needed, up to five days | Oral route | 2026-09-21 to 2026-09-26 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 8 hours as needed for tooth pain, no more than 3,000 mg a day, for up to five days | Two tablets by mouth every 8 hours as needed, up to 3,000 mg a day | Oral route | 2026-09-21 to 2026-09-26 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-19 | Body height | 165 | cm | S |
| 2026-10-19 | Body weight | 69 | kg | S |
| 2026-10-19 | Body mass index (BMI) [Ratio] | 25.3 | kg/m2 | S |
| 2026-10-19 | Systolic blood pressure | 116 | mm[Hg] | S |
| 2026-10-19 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-10-19 | Heart rate | 72 | /min | S |
| 2026-10-19 | Respiratory rate | 14 | /min | S |
| 2026-10-19 | Body temperature | 36.6 | Cel | S |
| 2026-10-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-19 | Hemoglobin [Mass/volume] in Blood | 12.9 | g/dL | 11.6-15 g/dL | Normal | S |
| 2026-10-19 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 95 | fL | 80-100 fL | Normal | S |
| 2026-10-19 | Platelets [#/volume] in Blood by Automated count | 248 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-10-19 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 | U/L | 10-40 U/L | Normal | S |
| 2026-10-19 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 7-56 U/L | Normal | S |
| 2026-10-19 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 34 | U/L | 5-40 U/L | Normal | S |
| 2026-10-19 | Phosphatidylethanol [Mass/volume] in Blood | 22 | ng/mL | Below 20 ng/mL: abstinence or light drinking; 20 to 199: significant drinking; 200 or more: heavy drinking | High | S |
| 2026-10-19 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S |
Vital signs recorded on 2026-10-19; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 116/74, pulse 72 |
| Mouth | Treated lower right molar; no swelling |
| Abdomen | Soft; no liver enlargement |
| Psychiatric | Bright and engaged; no signs of intoxication or withdrawal |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Opioid use disorder (heroin), severe; in early remission in a controlled environment at intake, five weeks after release from custody; on buprenorphine; synthetic modern episode linked to her documented heroin use | active | confirmed | F11.20 | S — Synthetic modern coding of the documented heroin addiction; language is person-first, and the code does not change with a return to use. |
| Alcohol use disorder, moderate; synthetic modern episode linked to her documented heavier drinking after her mother's death | active | confirmed | F10.20 | S — Synthetic modern coding of the documented drinking; the liver disease reported in her last year is not coded, because it was documented long after the episode. |
| Acute periapical abscess of the lower right first molar with localized swelling, treated with an antibiotic and dental drainage; resolved | resolved | confirmed | K04.7 | S — Synthetic acute dental infection; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Buprenorphine dose, adherence, cravings, withdrawal, and side effects | Every visit | Completed today | 16 mg daily without gaps; no cravings this month |
| Self-management | Visit frequency | Every 1 to 2 weeks in the first month after starting, then every 2 to 4 weeks until stable | Completed today | Stable; monthly visits from now |
| Laboratory | Urine drug testing, including fentanyl, explained as part of care rather than as a test of trust | At the start, then about monthly early in treatment and as needed | Completed today | Buprenorphine and norbuprenorphine only |
| Medication safety | Prescription drug monitoring program check | Before each buprenorphine prescription | Completed today | Only the dental prescriptions from the sick visit, which were not opioids |
| Medication safety | Naloxone at home and in her bag, and a trained companion | At the start; check and replace at each visit | Completed today | In date at home and in her bag |
| Medication safety | Prescription continuity on tour (pharmacy, prior authorization, travel letter) | Before each tour | Completed today | Early fill and travel letter worked on the last tour |
| Self-management | Counseling and peer recovery support | Offered to everyone; not a condition of medication | Completed today | Counseling weekly; peer coach every two weeks |
| Self-management | Oral care on sublingual buprenorphine | At the start and yearly | Completed today | Abscess treated; dental review every six months |
| Survey | Drinking and PEth | PEth at intake and at each check while drinking continues; AUDIT-C yearly | Completed today | PEth 22 ng/mL; AUDIT-C 3 at the preventive visit |
| Medication safety | Acamprosate adherence and kidney function | Kidney function before starting; adherence every visit | Completed today | Taking all three doses |
| Medication safety | Thiamine | While drinking heavily | Completed today | Stopped today; drinking is light |
| Laboratory | Liver tests (AST, ALT, GGT, albumin, bilirubin) | At intake, then every 1 to 3 months while drinking is heavy, and yearly | Completed today | AST 30, ALT 26, GGT 34 U/L, normal |
| Laboratory | Blood count | At intake and with liver tests while drinking | Completed today | Hemoglobin 12.9 g/dL, MCV 95 fL (from 101), platelets 248 |
| Laboratory | FIB-4 fibrosis score | At intake; repeat in 6 to 12 months with ongoing drinking, and every 1 to 2 years | Completed today | 0.78, low risk; repeat yearly |
| Imaging | Vibration-controlled transient elastography | If FIB-4 is 1.3 or higher | Not indicated | FIB-4 below 1.3 |
| Laboratory | Hepatitis C, hepatitis B, and HIV testing | At entry to care, then yearly while any drug use continues | Due | Nonreactive at intake; repeat at the intake anniversary |
| Self-management | Hepatitis A and B vaccines | Hepatitis B two doses 4 weeks apart; hepatitis A two doses 6 months apart | Completed today | Hepatitis A dose 2 given today; both series complete |
| Self-management | Influenza vaccine | Each autumn | Completed today | Given today |
| Survey | Depression screen (PHQ-9) | At intake and at each recovery visit while symptoms are present | Completed today | PHQ-9 4, from 9 at intake and 11 at three months |
| Survey | Suicide and overdose risk review, safety plan, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; the 988 Suicide & Crisis Lifeline in her phone |
Goal progress:
Immunizations given today: Hepatitis A vaccine, adult, dose 2 of 2; Influenza vaccine, 2026-2027 season [S]
Guideline basis: The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Treatment Options for Substance Use Disorder (medications for opioid and alcohol use disorders) (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019); AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis (2025); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); Adult Immunization Schedule by Medical Condition and Other Indication (2026); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Monthly buprenorphine visits. Counseling weekly. Liver tests, FIB-4, and infection screening at one year. [S]